Compare TFX & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | BLCO |
|---|---|---|
| Founded | 1943 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | TFX | BLCO |
|---|---|---|
| Price | $109.97 | $17.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 14 |
| Target Price | ★ $139.88 | $17.31 |
| AVG Volume (30 Days) | ★ 732.0K | 369.2K |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,189,988,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $9.90 | $8.06 |
| Revenue Next Year | $10.51 | $5.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.42 | ★ 6.23 |
| 52 Week Low | $102.58 | $10.45 |
| 52 Week High | $185.94 | $18.34 |
| Indicator | TFX | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 57.58 |
| Support Level | $108.39 | $16.22 |
| Resistance Level | $127.49 | $17.55 |
| Average True Range (ATR) | 3.05 | 0.35 |
| MACD | -1.50 | -0.02 |
| Stochastic Oscillator | 10.79 | 74.44 |
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.